Development of vaccines for Chagas disease (CRUZIVAX): stakeholders' preferences and potential impacts on healthcare
Ramponi, F.; Aerts, C.; Sartor, P.; Pinazo, M.J.; Freilij, H.; Guzmán, C.A.; Malchiodi, E.; Sicuri, E.
Gaceta Sanitaria 37 (2023) 102275
This study aims to inform the development of two vaccines for the prevention and treatment of Trypanosoma cruzi infection, and guide their pre-clinical phase up to clinical phase I. The three main objectives are: 1) to explore patients’ and policy makers’ preferences on the candidate vaccines in Argentina and Spain; 2) to investigate health-related quality of life of patients affected by Chagas disease; and 3) to assess the potential health provider savings associated with the vaccines, in terms of resource use and health care costs.
CRUZIVAX public deliverables
D16.1: A PowerPoint presentation of the project
D16.2: A PowerPoint presentation of the Cruzivax project website
Click deliverable to download.
When available, further results will be made public here and on our Zenodo Community.
This project has received funding from the European Union’s Horizon 2020 research and innovationprogramme under grant agreement No 815418.